Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$234.38 USD

234.38
566,922

+5.27 (2.30%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $234.35 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sheraz Mian headshot

Top Stock Reports for TotalEnergies, America Movil & Palo Alto Networks

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including TotalEnergies SE (TTE), America Movil, S.A.B. de C.V. (AMX) and Palo Alto Networks, Inc. (PANW).

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.

LabCorp (LH) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of 1.97% and 2.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.

What's in the Cards for Medtronic (MDT) in Q3 Earnings?

by Zacks Equity Research

Severe currency headwinds are expected to have affected Medtronic's (MDT) profitability in fiscal Q3.

LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth

by Zacks Equity Research

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical

by Zacks Equity Research

McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.

STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.

Indrajit Bandyopadhyay headshot

5 Dental Supplies Stocks to Buy Amid Recovering Prospects

by Indrajit Bandyopadhyay

Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.

AmerisourceBergen (ABC) Q1 Earnings Top, EPS View Raised

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal first-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

Boston Scientific (BSX) Q4 Earnings Miss, Operating Margin Up

by Zacks Equity Research

Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) dental business is likely to have gained in Q4 from the acquisition of Midway Dental.

Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase

by Zacks Equity Research

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.

Are Investors Undervaluing Laboratory Corp. of America (LH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Stryker's (SYK) Q4 Earnings Beat Estimates, Volume Improves

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs adversely impact margins.

Philips' (PHG) Q4 Earnings Down Y/Y, Supply Chain Issues Ease

by Zacks Equity Research

Koninklijke Philips' (PHG) Q4 top and bottom-line results reflect easing supply chain constraints.

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ongoing sales rebound in the base business for the Diagnostics and Drug Development segments likely drive LabCorp (LH) Q4 revenues.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls

by Zacks Equity Research

ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.

McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

What's in the Cards for Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research

Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.